MARKET

CHRS

CHRS

Coherus Bioscien
NASDAQ
1.130
-0.070
-5.83%
After Hours: 1.151 +0.021 +1.81% 17:57 02/06 EST
OPEN
1.190
PREV CLOSE
1.200
HIGH
1.210
LOW
1.130
VOLUME
1.25M
TURNOVER
--
52 WEEK HIGH
2.870
52 WEEK LOW
0.6603
MARKET CAP
130.19M
P/E (TTM)
-12.6682
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CHRS last week (0127-0131)?
Weekly Report · 3d ago
SA Asks: Which Big Pharmas would be most impacted by higher tariffs?
Seeking Alpha · 5d ago
Weekly Report: what happened at CHRS last week (0120-0124)?
Weekly Report · 01/27 10:03
Barclays Keeps Their Buy Rating on Coherus Biosciences (CHRS)
TipRanks · 01/27 09:36
RDY Q3 Earnings Match Estimates, Generics Revenues Rise Y/Y, Stock Down
NASDAQ · 01/24 16:07
Coherus Biosciences Awarded $27,626,788.30 Contract From Department Of Veterans Affairs For Pharmaceutical Preparation Manufacturing
Benzinga · 01/23 20:40
Coherus BioSciences Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 01/23 12:08
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target
Benzinga · 01/23 11:58
More
About CHRS
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a highly selective, cytolytic anti-CCR8 antibody, which is in a Phase I study in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via the pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, and UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta.

Webull offers Coherus Biosciences Inc stock information, including NASDAQ: CHRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CHRS stock methods without spending real money on the virtual paper trading platform.